RxDoctor Payments DataLook up a doctor →

Geovanna Deese

Nurse Practitioner · Charlotte, NCNPI 1558534768

Payments from drug & device makers

$25,698in general payments, 2019–2025

Across 1,448 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$5K
  • QOL Medical, LLC$2K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Ardelyx, Inc.$1K
  • plus $10K from 36 others

What the payments were for

  • Travel & lodging$1611%
  • Food & beverage$25,13998%
  • Education$3982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,698 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,782
Medicare patients
216
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide233$241,451
XifaxanRifaximin40$128,334
IbsrelaTenapanor Hcl51$107,427
TrulancePlecanatide90$82,731
CreonLipase/Protease/Amylase22$55,409
DificidFidaxomicin11$53,010
ZenpepLipase/Protease/Amylase15$39,911
MotegrityPrucalopride Succinate37$30,029
Dexlansoprazole DrDexlansoprazole73$18,678
ViberziEluxadoline11$16,960
VoqueznaVonoprazan Fumarate26$16,240
Lubiprostone104$14,135
Mesalamine21$14,130
Sucralfate77$10,501
Alosetron Hcl18$8,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Viberzi$5,369$313,820266 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$4,651$211,065130 claims
Ardelyx, Inc.Ibsrela$1,085$107,42751 claims
MerckDificid$377$53,01011 claims
Aimmune Therapeutics, Inc.Zenpep$514$39,91115 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,428$30,02937 claims
Phathom Pharmaceuticals, Inc.Voquezna$688$16,24026 claims
Redhill Biopharma Inc.Movantik$138$6,59912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →